https://www.selleckchem.com/ Gastrointestinal fistulation has been widely reported as an adverse effect of nicorandil therapy in Europe. People who have underlying diverticular disease are most at risk of this side-effect. In Western countries, diverticular disease is highly prevalent and can be clinically silent. This study aimed to identify diverticular disease genetic risk scores associated with early nicorandil stoppage, a surrogate marker for drug intolerance. A case-control study was carried out on 1,077 patients from the Genetics of Diabetes Audit and Research Tayside Scotland (GoDARTS) database. Cases were defined as having less then 9 nicorandil prescriptions with no identifiable reason for stopping (n=230). Controls had either ≥ 9 prescriptions, treatment continuation to death/study end or stoppage post myocardial infarction. Two diverticular genetic risk scores were created and used in logistic regression models. Isosorbide mononitrate was used as a control analysis. Patients with a raised diverticular genetic risk score, based on 23 replicable loci, had increased risk of stopping nicorandil therapy early (univariate [OR 2.26 p=0.04], multivariate [OR 3.96 p=0.01]). Similar trends were noted when using the full 42 variant diverticular score but statistical significance was not reached. The isosorbide control analysis did not reach statistical significance. Our analysis demonstrates a novel positive association between a raised diverticular genetic risk score and early stoppage of nicorandil therapy.Background Controversy exists regarding anticoagulation management following acute cardioversion in patients with early-onset ( less then 48 hours) atrial fibrillation without class I guideline indication for long-term oral anticoagulation (CHA2DS2-VASc 0-1). Methods and results A random-effect meta-analysis of observational studies reporting 30-day incidence of thromboembolic complications after cardioversion without post-procedural oral anticoagulation therap